.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Fish and Richardson
Deloitte
Julphar
Mallinckrodt
Baxter
Cipla
Daiichi Sankyo
Argus Health

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201532

« Back to Dashboard
NDA 201532 describes HALAVEN, which is a drug marketed by Eisai Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the HALAVEN profile page.

The generic ingredient in HALAVEN is eribulin mesylate. One supplier is listed for this compound. Additional details are available on the eribulin mesylate profile page.

Summary for 201532

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:4

Pharmacology for NDA: 201532

Physiological EffectMicrotubule Inhibition

Suppliers and Packaging for NDA: 201532

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HALAVEN
eribulin mesylate
SOLUTION;INTRAVENOUS 201532 NDA Eisai Inc. 62856-389 62856-389-01 1 VIAL in 1 CARTON (62856-389-01) > 2 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength1MG/2ML (0.5MG/ML)
Approval Date:Nov 15, 2010TE:RLD:Yes
Regulatory Exclusivity Expiration:Jan 28, 2023
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY
Regulatory Exclusivity Expiration:Jan 28, 2019
Regulatory Exclusivity Use:TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.
Patent:► SubscribePatent Expiration:Jul 20, 2023Product Flag?Substance Flag?YDelist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
Accenture
Argus Health
Express Scripts
Citi
Deloitte
US Department of Justice
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot